Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reissue Patent
2007-06-26
2007-06-26
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C552S653000
Reissue Patent
active
10986575
ABSTRACT:
The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability.
REFERENCES:
patent: 4435325 (1984-03-01), Jolly et al.
patent: 4866048 (1989-09-01), Calverley et al.
patent: 5292727 (1994-03-01), Godtfredsen
patent: 59-104358 (1984-06-01), None
patent: WO8700834 (1987-02-01), None
Thavarajah et al. “1,25(OH)2D3 and Calcipotriol (MC903) have similar effects on the induction of osteoclast-like cell formation in human bone marrow cultures”. Biochemical and Biophysical Research Communications, vol. 171, No. 3, Sep. 28, 1990, pp. 1056-1063.
Bagot et al., “Immunosuppressive effects of 1,25-dihydroxyvitamin D3 analog (Calcipotriol) on epidermal cells”. Chemical Abstracts, vol. 119, No. 5, Aug. 2, 1993, Abstract No. 41719, p. 182, col. 1, see abstract and Proc. Workshop Vitamin D (8th) 1991, pp. 518-519.
Braeutigam et al., “Effects of calcipotriol (MC903) and calcitriol after topical application on the skin of hairless rats. Much lower effect of calcipotriol on systemic calcium homeostasis”. Chemical Abstracts vol. 117, No. 21, Nov. 23, 1992, abstract #205159, p. 93, col. 1, see abstract & Skin Pharmacol. vol. 5, No. 2, 1992, pp. 87-92.
Kragblle et al., “Vitamin D analogs in the treatment of psoriasis”. Chemical Abstracts, vol. 116, No. 25, Jun. 22, 1992, abstract No. 248622, p. 90, col. 1, see abstract & J. Cell. Biochem. vol. 49, No. 1, 1992, pp. 46-52.
Larsen et al., “Structure and absolute configuration of a monohydrate of calcipotriol (1.alpha.,3,5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol”, Acta Crystallographica, Section C, Crystal Structure Communications, vol. 49, No. 3, 1993, pp. 618-621, see the whole document.
Andersen Niels Smidt Rastrup
Hansen Erik Torngaard
Ringborg Lene Hoffmeyer
Badio Barbara P.
Birch & Stewart Kolasch & Birch, LLP
Leo Pharma A/S
LandOfFree
Crystalline form of a vitamin D analogue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline form of a vitamin D analogue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline form of a vitamin D analogue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3812013